AbSci Announces Strategic Investment by Merck Global Health Innovation Fund
News provided by
Share this article
Share this article
VANCOUVER, Wash., Feb. 22, 2021 /PRNewswire/ AbSci, a pioneering synthetic biology company that unifies biologic drug discovery and development processes, today announced a strategic equity investment by Merck Global Health Innovation Fund (Merck GHI) and potential discovery collaborations with Merck Research Laboratories.
AbSci founder and CEO Sean McClain said, It has been terrific to work with Merck on many levels. We are pleased to be able to add value and bring solutions to tough problems. With the success of our initial projects, as well as this investment from Merck GHI, we have set in place a foundation upon which to build out a broad and mutually beneficial partnership with Merck. Everyone we have worked with at Merck shares the goal of helping the most patients with the best medicines as quickly as possible.
Rochester phone app firm evolves into $925 million heart monitor maker
The story of how a group of southeastern Minnesota software developers ended up creating one of the top remote cardiac monitor devices in the world starts with Rochester’s mix of cutting-edge technology and innovative health care. 5:30 am, Feb. 20, 2021 ×
Preventice co-founders, from left, Scott Burrichter, Jon Otterstatter and Greg Wobig Tuesday, Feb. 16, 2021, in Rochester. Preventice is being acquired by Boston Scientific. (Joe Ahlquist / jahlquist@postbulletin.com)
In 2007, four men sitting around a table in Rochester hammered out a rough idea to start a smartphone app firm. Their plans later morphed into a remote heart monitor manufacturer purchased by Boston Scientific for $925 million in cash in January.
• Big Data/Cloud-Based Solutions
Innovator applications will be accepted through March 7
th and up to three solutions will be selected in June to be evaluated in rapid-cycle studies with end-users, providing key validation data and actionable insights on design, feasibility, and market potential. There is zero cost to apply, zero cost to participate, and zero equity by HITLAB. Interested innovators and start-ups should apply today.
ABOUT HITLAB BREAKTHROUGH ALLIANCE
For over twenty years, HITLAB has been a pioneer in the advancement of digital health research, strategy and education. In 2016, the New York City Economic Development Corporation (NYCEDC) partnered with HITLAB to launch the Digital Health Breakthrough Network (DHBN) as part of its broader efforts to facilitate growth in New York City’s healthcare and life sciences sectors. HITLAB now operates this program independently and continues to provide prototype testing services to the digital
National Digital Health Experts Convene to Review Key Takeaways from the Exclusive Conference and Share Major Developments Which Will Shape Healthcare Beyond 2021.
New York, NY (PRUnderground) January 20th, 2021
Only twenty-four hours remain before digital health experts from all around the world step onto HITLAB’s virtual stage for a symposium covering the exciting developments from JPM Health Week. Join HITLAB on Thursday, January 21
st, from 11:00am to 2:00pm EST, for a broad-ranging discussion of the news and headlines generated from the 39th J.P. Morgan Healthcare Conference and the dozens of co-scheduled, adjacent events.
“InterSystems is excited to be sponsoring HITLAB’s Review of the 39th J.P. Morgan Healthcare Conference. We are proud to be joining our worldwide colleagues and digital health experts for this fast-paced symposium,” said InterSystems Senior Advisor Lynda Rowe.
Worldwide (PRUnderground) January 18th, 2021
HITLAB is excited to announce the HITLAB Breakthrough Alliance (BTA), has named Bill Taranto, president of Merck Global Health Innovation Fund, Chair of the HITLAB Breakthrough Alliance through 2024. The HITLAB Breakthrough Alliance is a membership-based health consortium whose mission is to verify and diffuse digital health innovations through the generation of exclusive, evidence-based research and insights.
BTA evolved from the Digital Health Breakthrough Network (DBHN), which was a five-year partnership between HITLAB and the New York City Economic Development Corporation. DBHN spurred the successful diffusion of such startups as Biotia, KnowNow, Tatch, and Bonbouton. These innovations addressed a range of healthcare needs from motor skills therapies to sleep disorders.